Robust exports allowed GM Korea Co. to post sales of 40,544 vehicles in September, up 89.5 percent from the 21,393 units in the same period last year.
The South Korean unit of General Motors Co. sold 6,097 units domestically last month, surging 17.9 percent from 5,171 a year ago with the Chevrolet Spark selling the most with 2,689 units.
Exports more than doubled to 34,447 from 16,222 during the same period, it said. GM Korea's exports have been up an on-year basis for three consecutive months, with strong demand for the Trailblazer SUV helping push up the monthly sales.
GM Korea vice president of sales, service, and marketing, Cesar Toledo said the firm is fully committed to gaining momentum and increasing sales
For the first nine months, GM Korea's sales plummetted 12.9 percent to from 308,933 in the same period of last year to 268,961 autos.
Domestic sales improved 11.4 percent to 60,075 units in the first nine months from the 53,934 in the same period last year, while exports plunged 18.1 percent to 208,886 from 254,999.


China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth
Google Secures Pentagon AI Deal for Classified Projects
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 



